China Approves Leqembi® for Alzheimer’s Treatment: A New Hope in the Fight Against Cognitive Decline
Introduction
Leqembi® Arrives in China for Alzheimer’s Care
Eisai, in partnership with BioArctic AB, has announced China’s approval of Leqembi® (乐意保), a groundbreaking treatment for mild cognitive impairment and mild dementia in Alzheimer’s disease. Following its success in the United States and Japan, this approval marks a significant stride in global healthcare.
Understanding Alzheimer’s and Leqembi’s Mechanism
How Leqembi® Tackles Alzheimer’s
In Alzheimer’s disease, an imbalance in the production and clearance of Amyloid-beta (Aβ) proteins causes memory loss and brain function impairment. Leqembi® actively targets both soluble and insoluble Aβ aggregates. This unique approach significantly slows the disease’s progression.
Clinical Evidence and Global Reach
Leqembi’s Journey: From Trials to Worldwide Approval
Based on the comprehensive global Phase 3 Clarity AD study, China’s approval of Leqembi® reflects its effectiveness in meeting all primary and secondary goals. Presented at the 2022 CTAD conference and published in the New England Journal of Medicine, these results offer hope to the 17 million Chinese patients with Alzheimer’s-related conditions.
Eisai’s Comprehensive Strategy in China
Beyond Drug Distribution: Eisai’s Vision for Alzheimer’s Care
Eisai’s strategy in China encompasses more than just distributing the drug. It aims to raise awareness, improve diagnostic environments, and leverage the “Yin Fa Tong” online health platform. This holistic approach ensures a streamlined journey for Alzheimer’s patients, focusing on early consultation and post-treatment follow-up.
BioArctic and Eisai: Collaborative Efforts
Partners in Progress: BioArctic’s and Eisai’s Commitment to Alzheimer’s Treatment
Since 2005, BioArctic has been collaborating with Eisai on developing and commercializing drugs for Alzheimer’s treatment. Eisai leads the clinical development and commercialization of Leqembi®, while BioArctic enjoys rights to payments, royalties, and Nordic commercialization, pending European approval.
Conclusion
Leqembi®: A Ray of Hope in Alzheimer’s Battle
Leqembi’s approval in China signifies a vital advancement in the fight against Alzheimer’s. BioArctic and Eisai continue working together, bringing optimism to millions affected by this disease worldwide.
